布地奈德肠溶胶囊,下一个重磅炸弹

赛柏蓝
Feb 26

IgA 肾病治疗药物来到爆发式增长前夜。01下一个重磅炸弹上市药品少、市场空间大,一度使得IgA肾病成为 创新药 企的“兵家必争之地”。作为全球首个获批的 IgA 肾病对因治疗药物,布地奈德肠溶胶囊(商品名:耐赋康/Nefecon/Tarpeyo)被视为下一个重磅炸弹药物。 西南证券 预测,布地奈德肠溶胶囊的销售额可能在2030年达到50亿体量。布地奈德肠溶胶囊已然初显王者风范。2024年,在未...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10